Clinical transplantation · 2025
Clinical Characteristics and Outcomes of Influenza-Associated Late-Onset Severe Pneumonia After Allogeneic Hematopoietic Stem Cell Transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yuewen, Cao Leqing, Zhang Xiaohui, Xu Lanping, Wang Yu, Yan Chenhua, Chen Huan, Chen Yuhong, Han Wei, Wang Fengrong, Wang Jingzhi, Huang Xiaojun, Mo Xiaodong
Аннотация
BACKGROUND: Late-onset severe pneumonia (LOSP) is one of the most important causes of mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The influenza virus is a frequent viral pathogen in patients receiving allo-HSCT, accounting for at least 30% of all respiratory viral infections. We aimed to identify the clinical characteristics and outcomes of influenza-associated LOSP after allo-HSCT.
METHODS: This study enrolled 23 patients who underwent allo-HSCT at the Peking University Institute of Hematology and were subsequently diagnosed with influenza-associated LOSP. Survival analysis was conducted via the Kaplan‒Meier method. Potential risk factors for survival and mortality following influenza-associated LOSP were evaluated through univariate and multivariate Cox regression analyses.
RESULTS: Among the patients, 39.1% (n = 9) died following influenza-associated LOSP. The median time from allo-HSCT to influenza infection was 269 days (range 100-3979 days), and the median time from the onset of influenza symptoms to influenza-associated LOSP was 5 days (range 0-38 days). The most common clinical manifestations were fever (95.7%), cough (56.5%), and expectoration (34.8%). After antiviral therapy, the median time for the influenza virus to turn negative was 11 days (range, 4-34 days). The 100-day cumulative incidence of influenza-associated LOSP-related mortality was 30.9% (95% CI 11.3%-50.5%). The probability of overall survival at 100 days after influenza-associated LOSP was 59.1% (95% CI 41.5%-84.0%).
CONCLUSIONS: This study presents the first comprehensive analysis of the clinical characteristics and outcomes associated with influenza-related LOSP following allo-HSCT. Additionally, our findings highlight the treatment strategies and prognostic factors associated with influenza-associated LOSP.
METHODS: This study enrolled 23 patients who underwent allo-HSCT at the Peking University Institute of Hematology and were subsequently diagnosed with influenza-associated LOSP. Survival analysis was conducted via the Kaplan‒Meier method. Potential risk factors for survival and mortality following influenza-associated LOSP were evaluated through univariate and multivariate Cox regression analyses.
RESULTS: Among the patients, 39.1% (n = 9) died following influenza-associated LOSP. The median time from allo-HSCT to influenza infection was 269 days (range 100-3979 days), and the median time from the onset of influenza symptoms to influenza-associated LOSP was 5 days (range 0-38 days). The most common clinical manifestations were fever (95.7%), cough (56.5%), and expectoration (34.8%). After antiviral therapy, the median time for the influenza virus to turn negative was 11 days (range, 4-34 days). The 100-day cumulative incidence of influenza-associated LOSP-related mortality was 30.9% (95% CI 11.3%-50.5%). The probability of overall survival at 100 days after influenza-associated LOSP was 59.1% (95% CI 41.5%-84.0%).
CONCLUSIONS: This study presents the first comprehensive analysis of the clinical characteristics and outcomes associated with influenza-related LOSP following allo-HSCT. Additionally, our findings highlight the treatment strategies and prognostic factors associated with influenza-associated LOSP.